Related Experiment Video

Updated: Feb 20, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Haematological cancer: Extended EFS with rituximab

Diana Romero

    Nature Reviews. Clinical Oncology
    |October 18, 2017
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    11.1K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.9K

    Related Experiment Videos

    Last Updated: Feb 20, 2026

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    3.9K
    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    11.1K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.9K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.8K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K

    Articles linked to this work by shared authors, journal, and citation graph.

    A Qualitative Study of Physicians' Decision-Making in Four US States With Abortion Bans.

    Perspectives on sexual and reproductive health·2026

    High-Risk Vascular Remodeling in Takayasu Arteritis: Descending Aortic Multilobulated Saccular Aneurysms and Aortic Coarctation.

    JACC. Case reports·2026

    New Yorkers Speak Up: Community Perspectives on Improving Healthcare Experiences in New York City.

    Journal of urban health : bulletin of the New York Academy of Medicine·2025

    Exploring the landscape of targetable alterations in patients with glioblastoma.

    Nature reviews. Clinical oncology·2026

    AI-based augmentation of oncology clinical trials.

    Nature reviews. Clinical oncology·2026

    Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

    Nature reviews. Clinical oncology·2026

    De-escalation trials in multiple myeloma: past, present and future.

    Nature reviews. Clinical oncology·2026

    Towards liquid biopsy-based analysis of antitumour immunity.

    Nature reviews. Clinical oncology·2026

    CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

    Nature reviews. Clinical oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us